Two hundred and ten bronchoalveolar lavage (BAL) samples were obtained from 50 patients 10 days before and on defined days after allogeneic bone marrow transplantation (BMT). The samples were examined for human cytomegalovirus (HCMV) and human herpesvirus-6 (HHV-6) by polymerase chain reaction (PCR). Fifteen patients (30%) had a positive result for HCMV in at least one sample and 25 (50%) were positive for HHV-6 in at least one sample. Five patients developed HCMV-associated interstitial pneumonia (HCMV-IP) within 100 days after allogeneic BMT. Four of these patients were positive for both HCMV and HHV-6. Conspicuous HHV-6 positivity was detected in BAL samples obtained because of respiratory symptoms. No association was found between detection of HHV-6 and acute graft-versus-host disease. Engraftment failure or a delay in engraftment was observed in none of the 50 patients. The data from this study indicate that HHV-6 is a pathogen in HCMV-associated, as well as in non-HCMV-associated infectious lung disease after BMT. Bone Marrow Transplantation (2000) 26, 639-644.
Interstitial pneumonia after bone marrow transplantation (BMT) is a severe and life-threatening complication. About 80% of interstitial pneumonias (IP) occur between days 30 and 100 after allogeneic BMT. Human cytomegalovirus (HCMV) has been recognized as the most frequent pathogen involved. 1 IP caused by other viruses occurs less frequently, but often has a serious clinical outcome. IP associated with human herpesvirus-6 (HHV-6) was described in 1991 for the first time. 2 HHV-6, orginally referred to as human B-lymphotropic virus, was initially isolated in 1986 from peripheral blood leukocytes of patients with lymphoproliferative disorders and infection with the human immunodeficiency virus (HIV). 3 HHV-6 infection occurs early in life. At the age of 5 years, more than 90% of children are seropositive for the virus and by 17 years of age, 98%. 4 In 1988, HHV-6 was recognized as the causative agent of exanthema subitum. 5 It has also been associated with a mononucleosis-like illness, 6 chronic fatigue syndrome 7 and it has been proposed as a cofactor in AIDS. 8 HHV-6 persists in salivary and bronchial glands. 9 Latent virus was also detected in monocytes/macrophages 10 and it has been isolated from the peripheral blood monocytes of two kidney transplant patients. 11 Reactivation of HHV-6 is important especially in immunocompromised patients. 12 Immunologic and molecular studies based on restriction enzyme mapping analysis, reactivity to HHV-6-specific monoclonal antibodies, and in vitro growth characteristics have led to the distinction of two major variants, designated A and B. 13 Bone marrow transplant recipients more often harbor the B variant of HHV-6. 14, 15 After BMT the virus can be isolated from peripheral blood cells in 40-60% of recipients. It has also been associated with late graft failure 16 and fatal encephalitis. 17 HHV-6 can also cause post-transplant bone marrow suppression in BMT patients. 18 HHV-6-DNA is reportedly more frequently detected in patients with moderate or severe acute graft-versus-host disease (aGVHD) than in patients without aGVHD or with mild aGVHD. 19 The contribution of HHV6 to symptomatic respiratory tract disease and its role as coinfecting pathogen in HCMVassociated pneumonia is still unclear. The aim of the present retrospective study was to determine if HHV-6 can be identified as a potential pathogen in infectious lung disease after BMT. Further, whether detection of HHV-6-DNA by polymerase chain reaction (PCR) in patients after BMT is associated with an increased occurrence or severity of aGVHD and/or an engraftment failure was analyzed.
Patients and methods

Patients
In a retrospective study, BAL samples obtained from 50 unselected allogeneic BMT patients (27 male, 23 female) during 1991 and 1993 were analyzed. The study was approved by the local Board on Medical Ethics at the Essen University Hospital. The mean age of patients was 35 years (range, 18-56). BMT was performed on patients with acute myeloid leukemia (n = 16), chronic myeloid leukemia (n = 23), acute lymphoblastic leukemia (n = 7), multiple myeloma (n = 3) and Hodgkin's lymphoma (n = 1). Fortyone patients recieved bone marrow from HLA-identical and three patients from HLA-mismatched family donors. Six patients received bone marrow grafts from a unrelated donor (four HLA-identical, two HLA-mismatched). Two conditioning regimes were used, (1) consisting of cyclophosphamide (60 mg/kg/day × 2) either preceded or followed by fractionated total body irradiation (TBI, cobalt source, four daily fractions of 2.5 Gy) to a total dose of 10 Gy (n = 38); and (2) busulfan (4.0 mg/kg/day for 4 days) followed by cyclophosphamide (60 mg/kg/day × 2) (n = 12). Graft-versus-host (GVHD) prophylaxis was with short course methotrexate and cyclosporine A (37 patients), or cyclosporine A alone (13 patients) as previously published. 20 All patients seropositive for herpes simplex virus (n = 40) received prophylaxis with acyclovir from day 7 post transplantation (10 mg/kg/day for at least 10 days) and 29 patients received HCMV prophylaxis with ganciclovir from day 30 post transplantation (5 mg/kg/day for at least 14 days). All transplants were performed without prior ex vivo removal of donor lymphocytes from the graft. Irradiated leukocyte-depleted blood products were used exclusively for blood component substitution throughout the post-transplant course.
Assessment and grading of acute and chronic GVHD followed the commonly accepted clinical criteria as proposed by Gluckberg et al 21 and Thomas et al.
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Serology
HCMV serostatus of donors and recipients was performed by ELISA (Dade Behring, Liederbach, Germany). Twentythree patients were seronegative for HCMV prior to BMT. Out of those 23 patients only 13 also had a seronegative donor, while 10 patients were transplanted with material from a seropositive donor. Of these 27 patients seropositive for HCMV, 14 had a seronegative donor and 13 a seropositive donor. Because of the high prevalence of antibodies against HHV-6 virus of 98% in adults, 4 HHV-6-serostatus was not performed.
Bronchoalveolar lavage specimens
Serial fiber optic bronchoscopy examinations and BAL were performed 10 days before transplantation (BAL A) and on day 1 (BAL B), 30 (BAL C) and 40 (BAL D) post BMT to study infectious complications after BMT. Bronchoalveolar lavage was as follows. The upper airways were anesthetized with lignocaine spray, 100 mg, and the trachea with a 4% lignocaine solution, 200 mg. The bronchoscope was wedged into a subsegmental bronchus. Buffered saline solution, 20 ml, was infused into the lung through the bronchoscope and aspirated gently with the syringe. The procedure was repeated from five to 10 times. The last aliquot was sent to the laboratory. The cell free supernatant of BAL fluid was tested for HCMV-DNA and HHV-6-DNA by nested PCR.
Additional BALs were obtained from 10 patients because clinical symptoms of respiratory tract disease developed at later time points.
Detection of HCMV-DNA by PCR
DNA was isolated by phenol-chloroform extraction. 23 Precautions were taken to prevent contamination, as described by others. 24 One g of DNA in a 10 l volume was added to a volume of 40 l reaction mix containing PCR buffer (50 mmol/l KCl, 10 mmol/l Tris-HCl pH 8.3, 1.5 mmol/l MgCl 2 , 0.001% gelatin, Promega, Heidelberg, Germany), 1.25 mmol/l deoxynucleoside triphosphate, 50 pmol/l of each primer P1, 5′ATGGAGTCCTCTGCCAAGAG3′; P2, 5′CAATACACTTCATCTCCTCG3′. The reaction mixture was covered with mineral oil. After an initial denaturing step of 4 min at 94°C, 34 cycles of 1 min at 94°C, 1 min at 55°C and 2 min at 72°C were performed in an automated thermal cycler resulting in a 721-bp product of a sequence of the immediate-early protein region.
In the second round of PCR, 2.5 l of the first PCR products was added to a 50 l total volume containing PCR buffer, 50 mmol/l KCl, 10 mmol/l Tris-HCL pH 8.3, 1.5 mmol/l MgCl 2 , 0.001% gelatin (Promega), 1.25 mmol/l deoxynucleoside triphosphate, 50 pmol/l of each primer P3, 5′GTGACCAAGGCCACGACGTT3′ and P4, 5′TCTGCC AGGACATCTTTCTC3′. Amplification was performed as described in the first step of PCR. This PCR resulted in a 167-bp product. Sequences for primers P1, P2, P3 and P4 have been described previously. 25 HCMV-infected foreskin fibroblasts were used as positive control and water as negative control. A 1% agarose gel containing 5 g/ml ethidium bromide was used to separate and visualize PCR products.
Detection of HHV-6-DNA by PCR
A seminested PCR detecting a sequence of the polymerase gene for both variants A and B of HHV-6 was developed. The following primers were used: P1 5′ATTAT-ACCGCGAGGAAGTATAC3′, P2 5′GGGGCACATCTGT TGCGGTTTC3′, P3 5′TTAGACGAGTCCTACAGAA-GAA3′. One g of DNA in 10 l volume was used in a total volume of 50 l containing PCR buffer (50 mmol/l KCl, 10 mmol/l Tris-HCl pH 8.3, 1.5 mmol/l MgCl 2 , 0.001% gelatin, Promega), 1.25 mmol/l deoxynucleoside triphosphate, 50 pmol/l of each primer P1 and P2. The reaction mixture was covered with mineral oil. After an initial denaturing step of 4 min at 94°C, 34 cycles of 1 min at 94°C, 1 min at 55°C and 2 min at 72°C were performed in an automated thermal cycler resulting in a 333-bp product.
In the second round of PCR, 2.5 l of the first PCR products were added to a 50 l total volume containing PCR buffer, 50 mmol/l KCl, 10 mmol/l Tris-HCl pH 8.3, 1.5 mmol/l MgCl 2 , 0.001% gelatin (Promega), 1.25 mmol/l deoxynucleoside triphosphate, 50 pmol/l of each primer P1 and P3. After an initial denaturing step of 4 min at 94°C, 34 cycles of 1 min at 94°C, 1 min at 45°C and 2 min at 72°C were performed in an automated thermal cycler resulting in a 214-bp product. J Jhan cells infected with HHV-6 were used as positive control and water as a negative control. A 1% agarose gel containing 5 g/ml ethidium bromide was used to separate and visualize PCR products.
Sensitivity of the PCR assays
Products of the first round of PCR were extracted by gel extraction (Qiaquick Gel Extraction Kit; Qiagen, Hilden, Germany) following the instructions of the manufacturer. Extracted products were measured by photometry and end point dilutions of HCMV-, as well as HHV-6-DNA were performed to determine the sensitivity of the respective PCR reaction. A sensitivity of 1 copy/l was determined for both HCMV-PCR and HHV-6-PCR.
Engraftment
The duration of neutrophil recovery was defined by the time interval between the first day on which absolute blood neutrophil counts declined below 1000/l, and the first of 3 consecutive days, on which these counts exceeded 1000/l. Engraftment was assumed if self-sustaining blood neutrophil counts greater than 1000/l together with untransfused platelet counts were reached by day 30 post transplantation.
Statistics
Frequencies of variables were compared by the two-tailed Fisher's exact test from the contingency tables.
Results
Pulmonary complications
Two-hundred and ten BAL specimens obtained from 50 patients were analyzed for HCMV and HHV-6 by nested PCR in this study. Fifteen patients had a positive PCR result for HCMV in at least one BAL sample, and 25 patients tested positive by PCR for HHV-6 in at least one sample. Prophylaxis with acyclovir had no influence on PCR positivity for HCMV or HHV-6. Figure 1 provides data on the presence of HCMV-DNA and HHV-6-DNA in BAL fluid 10 days before and on days 1, 30 and 40 after BMT, respectively. If either HCMV-DNA was detected in BAL or the chest radiograph showed non-lobar infiltrates, treatment with ganciclovir was initiated.
Of 27 patients with HCMV antibody seropositivity before transplantation, 12 (44%) had at least one positive PCR test for HCMV and 16 at least one positive PCR test for HHV-6 (59%). A lower proportion of positive PCR tests for HCMV and HHV-6 was found in the 23 seronegative At least one sample was positive. DNA for both viruses was more frequently detected in HCMV-positive patients (Fisher's exact test, P = 0.0011 for HCMV-DNA and P = 0.0089 for HHV-6-DNA).
patients. HCMV was detected in only three of 23 patients (13%) and HHV-6 in eight of the 23 patients (35%). The differences observed for HCMV, as well as HHV-6 between HCMV-seropositve and seronegative patients were statistically highly significant (Table 1) . Five patients developed HCMV-IP during the first 100 days after transplantation with dyspnea, non-productive cough, hypoxemia, non-lobar radiographic infiltrates and detection of HCMV-DNA in BAL fluid. All five patients were seropositive for HCMV pretransplant, and two had a seropositive and three had a seronegative donor. In four patients HHV-6-DNA was detected additionally. HCMV-IP developed in two cases in spite of prophylactic therapy with ganciclovir (day 42 and 49 after BMT). Three patients not receiving ganciclovir prophylaxis developed pneumonia on day 48, 61 and 97 after BMT, respectively.
Ten patients underwent an additional BAL because of respiratory insufficiency (Table 2 ). In two cases HCMV-DNA, but in seven HHV-6-DNA was detected. In two of the latter a coinfection was found either with Pneumocystis carinii or with E. coli and C. glabrata.
Acute graft-versus-host disease
Acute GVHD occurred in 32 of 50 patients (64%). Nine patients (28%) developed aGVHD grade I and 19 (59%) The detection of either HCMV-DNA or HHV-6-DNA by PCR was not associated with an increased occurrence or severity of aGVHD. Of 19 patients who tested negative for both viruses in all BAL samples, seven had no signs of aGVHD, four developed aGVHD grade I, six aGVHD grade II, and two patients aGVHD grade III. Three of the six patients who tested positive only for HCMV-DNA in at least one sample after BMT developed no aGVHD, one aGVHD grade I and two aGVHD grade II.
Six of 16 patients with at least one positive PCR assay for HHV-6 developed no aGVHD. Two patients were diagnosed with grade I of aGVHD and seven with aGVHD grade II, whereas one developed aGVHD grade III (not significant).
Two of nine patients with positive PCR assays for both viruses had no signs of aGVHD. One patient developed aGVHD grade I, five aGVHD grade II and one aGVHD grade III (Table 3) .
Prophylactic therapy with ganciclovir and acyclovir had no influence on the development of aGVHD in this study.
Engraftment
Engraftment failure or delay in engraftment was observed in none of the 50 study patients. No significant differences were found in the median time to engraftment of all study subgroups. Patients who tested negative by PCR for both viruses had a median time to engraftment of 20.5 days. Patients who were positive only for HCMV-DNA or HHV-6-DNA engrafted at a median of 19.8 days and 19.5 days, respectively. A shorter time to engraftment with a median time of only 16.5 days (albeit not significant) was seen in patients who were PCR-positive for both viruses in at least one sample.
Discussion
The aim of the present study was to determine if the presence of HCMV is associated with an increased detection of HHV-6 by PCR in serially performed bronchoalveolar lavage samples obtained from patients 10 days before allogeneic BMT and up to 40 days thereafter. Additionally, the Table 3 GVHD in patients with or without positive viral PCR Statistically no correlation between detection of HCMV-DNA and/or HHV-6-DNA and occurence of aGVHD was found using Fisher's exact test.
Results of PCR
question was addressed if HHV-6 is a potential copathogen. We defined the term copathogen as infection with both HHV-6 and another pathogen particularly HCMV. Furthermore, we wanted to analyze if the detection of HHV-6 by PCR is associated with acute GVHD, engraftment failure or engraftment delay in patients after BMT. The detection of HHV-6 in BAL samples might be only found in clinically relevant HHV-6 infections or coinfections, since HHV-6 was not detectable in BAL samples from 34 HIV-1 infected patients with respiratory disorders tested for the presence of HCMV and HHV-6. In contrast, 12 samples tested positive for HCMV. 26 In the present study, HHV-6 was detected by seminested PCR in 25 of 50 patients (50%) in at least one sample after BMT, whereas HCMV was detected by PCR in only 15 of 50 patients (30%). These results are in accordance with data previously reported by others. 27, 28 In order to evaluate the role of HHV-6 as a pathogen, detection of HHV-6 by PCR in BAL samples was correlated with the patient's HCMV serostatus. In this analysis, HHV-6 was more often detected by PCR in patients (59%) who were seropositive for HCMV before transplantation than in patients who were seronegative for HCMV (35%).
Five HCMV seropositive patients developed HCMVassociated interstitial pneumonia (HCMV-IP). In all patients HCMV-DNA was detectable in at least one BAL sample. Four of the five patients were also positive for HHV-6 by PCR.
In seven of the BAL samples taken 61-455 days post BMT because of respiratory distress, HHV-6 was detected by PCR. Three patients with pneumonia had positive results for HHV-6 and were negative for HCMV by PCR. Although other pathogens besides HHV-6 were not identified in the BAL samples of these three patients, it remains unclear whether the pneumonia was caused by HHV-6 since lung biopsy specimens were not available.
In BAL samples of two further patients with infectious lung disease, HHV-6 was detected by PCR. In one patient sepsis with E. coli and C. glabrata was diagnosed and the other patient suffered from a Pneumocystis carinii pneumonia. A case of pneumonia and coinfection by HHV-6 and Legionella pneumophila in an immunocompetent adult was reported previously. 29 HHV-6 was isolated from a sample of peripheral blood during the acute stage of the illness and numerous HHV-6-infected macrophages and lymphocytes were detected in lung tissue.
The role of virus-virus interaction in viral reactivation between or among herpes viruses is not well studied. The simultaneous antibody rise to HCMV and HHV-6 may suggest genuine reactivation of both viruses. 30 Persistence of HHV-6 in bronchial glands appears important in the possible role as a copathogen in infectious lung disease. Furthermore, monocytes are major sites of persistence of both HHV-6 and HCMV. 31 In the two cases of HHV-6-IP reported by Carrigan et al, 2 the infected cells were primarily intra-alveolar macrophages. It remains to be clarified, however, by which mechanism different viruses may enter the same cell. In an in vitro experiment, Schonnebeck and co-workers 32 showed that HHV-6 infection of immature lymphoid cells renders the cytoplasmatic membrane rigid and leads to an increased expression of receptor proteins for viruses, for example CD4 for HIV-1 and CR2 for Epstein-Barr virus (EBV). The authors conclude that HHV-6 infection may predispose to superinfection of cells with other viruses. Moreover, HHV-6 might also be able to induce replicative cycles in other herpes viruses. Flamand et al 33 showed that infection of EBV genome-positive human lymphoid cell lines with HHV-6 results in EBV reactivation in these cells.
The demonstration that corticosteroids efficiently inhibit HHV-6 replication in vitro suggests that the virus is able to enhance tissue inflammation and pave the way for infections by other pathogens. 29 An association between increased occurrence or severity of aGVHD and detection of HHV-6 as described by Wilborn et al 19 could not be confirmed. Furthermore, no single case of engraftment failure or delay in engraftment was observed. Our data confirm results reported previously that there is no association between aGVHD and engraftment failure and the detection of HHV-6. 34, 35 The data presented in this study show increased detection of HHV-6 in HCMV-IP and pneumonia caused by other pathogens. Furthermore, the results indicate that HHV-6 is a potentially important pathogen in infectious lung disease. Therefore HHV-6 PCR should be performed in patients with respiratory distress after allogeneic BMT.
